Phibro Animal Health (PAHC)
(Delayed Data from NSDQ)
$22.28 USD
-0.13 (-0.58%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $22.21 -0.07 (-0.31%) 7:50 PM ET
2-Buy of 5 2
A Value A Growth F Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$22.28 USD
-0.13 (-0.58%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $22.21 -0.07 (-0.31%) 7:50 PM ET
2-Buy of 5 2
A Value A Growth F Momentum A VGM
Zacks News
Innovation Aids Alcon Stock's Growth Despite Macroeconomic Troubles
by Zacks Equity Research
Banking on strong sales of its contact lenses and ocular health products, ALC is registering solid growth within Vision Care.
DGX Stock to Benefit From New Partnership With Sentara Health Plans
by Zacks Equity Research
Quest Diagnostics extends services in Virginia and Florida via a partnership with Sentara Health Plans.
TMO Stock to Gain From Expanded Bioanalytical Services in Sweden
by Zacks Equity Research
Thermo Fisher's PPD arm unveils a new facility in Sweden, expanding its bioanalytical capabilities.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
PAHC vs. ABT: Which Stock Is the Better Value Option?
by Zacks Equity Research
PAHC vs. ABT: Which Stock Is the Better Value Option?
CRL Stock to Gain From Strategic Neuroscience Partnership With CEBINA
by Zacks Equity Research
Charles River collaborates with CEBINA as part of the DanubeNeuro program to advance innovation in neurodegeneration.
Is Phibro Stock Worth Retaining in Your Portfolio Now?
by Zacks Equity Research
PAHC Animal Health business, supported by the flourishing vaccine product line, drives optimism for future growth. However, macroeconomic impacts are a concern.
PAHC Stock Gains From Innovation, Market Expansion Goal
by Zacks Equity Research
Phibro Animal Health's nutritional product offerings, such as OmniGen-AF and Animate, are being increasingly used in the global dairy industry.
Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are You Looking for a Top Momentum Pick? Why Phibro Animal Health (PAHC) is a Great Choice
by Zacks Equity Research
Does Phibro Animal Health (PAHC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Implied Volatility Surging for Phibro Animal Health (PAHC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Phibro Animal Health (PAHC) stock based on the movements in the options market lately.
PAHC vs. ABT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PAHC vs. ABT: Which Stock Is the Better Value Option?
Here's Why Phibro Animal Health (PAHC) is a Strong Momentum Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Phibro (PAHC) International Revenue Performance Explored
by Zacks Equity Research
Examine the evolution of Phibro's (PAHC) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Here's Why Phibro Animal Health (PAHC) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Phibro Q4 Earnings and Revenues Beat, Operating Margin Down
by Zacks Equity Research
PAHC's impressive fourth-quarter fiscal 2024 results can be attributed to the Animal Health segment's robust performance.
Here's What Key Metrics Tell Us About Phibro (PAHC) Q4 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Phibro (PAHC) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Phibro Animal Health (PAHC) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Phibro (PAHC) delivered earnings and revenue surprises of 20.59% and 4.09%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Phibro (PAHC) Stock Jumps 10.2%: Will It Continue to Soar?
by Zacks Equity Research
Phibro (PAHC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Broad Portfolio to Aid Patterson Companies' (PDCO) Q1 Earnings
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal first-quarter results are likely to reflect an improvement in both the Dental and Animal Health segments on the back of comprehensive product offerings.
Should Value Investors Buy Phibro Animal Health (PAHC) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Countdown to Phibro (PAHC) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Phibro (PAHC), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.
ICU Medical, Inc. (ICUI) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
ICU Medical (ICUI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Phibro Animal Health (PAHC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Phibro (PAHC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quipt Home Medical Corp. (QIPT) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Quipt Home Medical (QIPT) delivered earnings and revenue surprises of -500% and 1.64%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?